What we do Dishman Carbogen Amcis Limited is a global contract development and manufacturing organization (CDMO) specializing in APIs, high-potency APIs, vitamin D analogues, and specialty chemicals. |
Founded in 1,983 |
Market share Strong presence in global markets; known for expertise in niche APIs and oncology segments, with regulatory approvals from major health authorities including USFDA and European agencies. |
Problem solved Provides customized drug development and manufacturing services to pharma companies addressing therapeutic areas like oncology and specialty medicines efficiently and at scale. |
Top clients or who we serve Serving global pharmaceutical innovators, biotech firms ranging from small to large entities across regions including India, Europe, US, China, and Japan; B2B focus. |
Key management Arpit J. Vyas (Global Managing Director) with extensive industry experience, joined by a global leadership team across India and Switzerland sites. |
Our journey and innovations Since 1983, evolved through acquisitions and expansions across India, Europe, and Asia; pioneered high-potency API manufacturing with state-of-the-art multipurpose facilities and advanced R&D. |
Where we operate Operations in India, Switzerland, UK, France, Netherlands, China, Singapore, and USA with multiple manufacturing and R&D sites serving global markets. |
Top products or what we offer APIs, high-potency APIs (HiPo), vitamin D analogues, cholesterol precursors, specialty chemicals, disinfectants, and contract manufacturing services including ADCs and bioconjugation. |
Top brands Carbogen Amcis and Dishman brands are key drivers; noted for market-leading HiPo manufacturing, specialized vitamin D analogues, innovative oncology APIs, and extensive GMP-certified facilities. |
Raw materials needed Specialty chemical precursors, raw materials for APIs, vitamin D analogues, cholesterol, and reagents for complex organic synthesis processes. |
Raw materials supplier Suppliers are global chemical and pharmaceutical raw material providers; the company actively diversifies vendors to optimize costs and ensure supply reliability. |
Recurring vs cyclical contribution Revenue driven primarily by recurring CDMO contracts with growth from late-phase development and commercial supply; marketable molecules provide steady cash flows. |
Our industry position Among top CDMOs globally with leadership in high-potency APIs and niche specialty chemicals, maintaining strong regulatory compliance and expanding commercial operations. |
Financial highlights Consolidated revenue Rs. 2711.5 Cr in FY 2024-25 with PAT Rs. 3.24 Cr showing turnaround from prior losses; EBITDA margin improving amid increased capacity utilization. |
Geographical revenue split Majority revenue from Rest of the World (approx Rs. 2104 Cr) and India contributing around Rs. 37 Cr, reflecting a strong global footprint. |
Order book - |
Whats driving growth Growth driven by oncology and specialty APIs, ADC business expansion, enhanced capacity in France and Switzerland, regulatory approvals, and technology integration across sites. |
Our future plans Capex focused on expanding manufacturing lines in France and Switzerland, enhancing ADC capabilities, digital transformation, and increasing market penetration in China and US. |
Our green promise Committed to environmental sustainability through zero discharge initiatives, ISO certifications (EMS, QMS, OH&S), and continual improvement in health, safety, and environment practices. |
Our people and values Over 2200 employees worldwide with a strong R&D focus; culture emphasizes innovation, sustainability, and collaboration across global teams. |
Key challenges ahead Managing raw material cost volatility, integrating global operations, geopolitical uncertainties, maintaining regulatory compliance, and competitive pressures in specialty CDMO markets. |
Interesting facts Operates one of Asia’s largest high-potency API facilities in Bavla, India; has 32 global R&D labs with over 50 PhDs; strong pipeline of 12 late Phase III molecules, especially in oncology. |
Risks and strategy Risk mitigation involves diversified supplier base, risk management framework, strong compliance monitoring, and strategic geographic expansion coupled with focused R&D investment. |
